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Abstract
w w ww  w11 x . x x x xThe agonist radioligand N- 2-hydroxy-5- 1-hydroxy-2- 2- 4- C -methoxyphenyl -1-methylethyl amino ethyl phenyl formamide
w11 x .C formoterol was synthesised in order to test its ability to visualise pulmonary b -adrenoceptors in vivo, with positron emission2
 . w11 xtomography PET . Formoterol was labelled via reaction of a dibenzyl-protected precursor with C CH I. Subsequent deprotection with3
w11 x  . y1PdrC and H yielded C formoterol in 5–15% corrected for decay and the specific activity ranged from 5.5–22.2 TBq mmol2
 y1. w11 x150–600 Ci mmol , 60–70 min after end of bombardment. Biodistribution studies with C formoterol were performed in male
 .  y1 .Wistar rats which were either untreated or predosed with D,L -propranolol hydrochloride 2.5 mg kg , b-adrenoceptor antagonist ,
 .  y1erythro-DL-1- 7-methylindan-4-yloxy -3-isopropylaminobutan-2-ol hydrochloride ICI 118551, 0.15 mg kg , b -adrenoceptor antago-2
.  y1 .  .  w   nist , isoprenaline 15 mg kg , non-subtype selective b-adrenoceptor agonist or " - 2-hydroxy-5- 2- 2-hydroxy-3- 4- 1-methyl-4-tri-
. . . . . x .  y1fluoromethyl 1H-imidazol-2-yl- phenoxy propyl amino ethoxy benzamide monomethane sulfonate CGP 20712A, 0.15 mg kg , b -1
. w11 xadrenoceptor antagonist . Lungs, heart, liver and plasma were analysed for radioactive metabolites. The kinetics of C formoterol in the
lungs of male Wistar rats were investigated by means of a dynamic PET study. The biodistribution studies showed significant specific
 .binding in tissues known to contain b -adrenoceptors lungs, spleen, and heart . Binding in these organs was blocked by ICI 118551 and2
w11 xisoprenaline, but not by CGP 20712A. C Formoterol was rapidly metabolised in rats but lungs and heart did not substantially take up
w11 xthe labelled metabolites. The binding of C formoterol in various tissues of rats is consistent with the b -selectivity of formoterol.2
w11 x w11 xWhether C formoterol selectively binds to the high affinity state of b -adrenoceptors remains to be elucidated. C Formoterol is2
potentially useful for studying b -adrenoceptors with PET and this radioligand may provide new insights in the mechanisms underlying2
prolonged sympathomimetic action. q 1998 Elsevier Science B.V. All rights reserved.
w11 xKeywords: C Formoterol; b -Adrenoceptor; Positron emission tomography; Lung2
1. Introduction
w w ww  w11 xN- 2-hydroxy-5- 1-hydroxy-2- 2- 4- C -metho-
. x x x xxyphenyl -1-methylethyl amino ethyl phenyl formamide
 .formoterol is a b -adrenoceptor agonist with interesting2
clinical features. Formoterol displays a high affinity K D
s1.05"0.17 nM, in human lung membranes Mak et al.,
..  .1994 and selectivity b :b s90:10 for the b -adrenoc-2 1 2
 .eptor Roux et al., 1996 . Addition of the non-hydrolysable
GTP analogue, GTPgS gave a reduction of the K andD
w3 xB , suggesting that the receptors labelled by H for-max
) Corresponding author. Tel.: q31-50-361-3183; Fax: q31-50-361-
1687; E-mail: t.j.visser@pet.azg.nl
moterol are coupled to a guanine nucleotide binding pro-
tein and that formoterol labels the high affinity state Mak
.et al., 1994 . Formoterol causes a long lasting bronchodila-
 .tion at least 12 h in man but only when the drug is
 .administered by inhalation Lofdahl and Svedmyr, 1989 .¨
It reduces asthma symptoms significantly and there is no
evidence of tolerance or tachyphylaxis in long-term studies
 .Johnson, 1995; Steffensen et al., 1995 . The mechanisms
causing the sustained activity are not fully understood yet.
In case of salmeterol, another long acting b -adrenoceptor2
agonist, it was explained by means of an exosite model
Bradshaw et al., 1987; Nials et al., 1993; Coleman et al.,
.1996 in which the ligand binds to an exosite close to the
receptor, resulting in prolonged activation. Another theory
0014-2999r98r$ - see front matter q 1998 Elsevier Science B.V. All rights reserved.
 .PII: S0014-2999 98 00694-3
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is the plasmalemma diffusion micro kinetic model, based
on the lipophilicity of formoterol and salmeterol Ander-
.son et al., 1994 . But lipophilicity is probably not the only
determinant, which governs the sustained action Linden et´
.al., 1996 . Knowledge about the in vivo pharmacokinetics
and metabolism of formoterol is of major importance
because delivery and metabolism may also influence the
kinetics of the bronchodilatory effect Jeppsson et al.,
.1989 .
 .With positron emission tomography PET it is possible
 .to study the behaviour and fate of radiolabelled receptor
ligands in vivo, e.g., their biodistribution, the plasma and
tissue kinetics, non-specific binding, and dose dependent
changes therein. Receptors can be studied in their natural
environment and their distribution and density can be
assessed. Here, we describe the synthesis of a novel ago-
w11 xnist radioligand C formoterol and its preclinical evalua-
tion in experimental animals.
2. Materials and methods
2.1. Compounds
 . w . x  .D,L -1- 1-Methylethyl amino -3- 1-naphthalenyloxy -
 . .2-propanol hydrochloride DL -propranolol hydrochloride
was obtained from Janssen Chimica, Tilburg, the Nether-
 .lands. Erythro-DL-1- 7-methylindian-4-yloxy -3-isopro-
pylaminobutan-2-ol hydrochloride ICI 118551 hydrochlo-
.ride was a gift from ICI pharmaceuticals, Macclesfield,
 .UK. " -Isoprenaline was obtained from Sigma, St. Louis,
 .  w   MO. " - 2-hydroxy-5- 2- 2-hydroxy-3- 4- 1-methyl-4-
. . . . .trifluoromethyl 1H-imidazol-2-yl- phenoxy propyl amino
x .  .ethoxy benzamide monomethane sulfonate CGP 20712A
was a gift from Ciba Geigy, Basle, Switzerland.
[11 ]2.2. The synthesis of C formoterol
w11 x w11 xC CH I was prepared from C CO , which was3 2
14  .11generated by the N p,a C nuclear reaction with 17
w11 xMeV protons. The C CO was trapped in the reaction2
vessel which was previously filled with 0.3 ml of a diluted
 .solution of lithium aluminum hydride LiAlH in tetrahy-4
drofuran THF, 0.15 ml of a saturated solution of LiAlH4
.in THF was diluted with THF to a final volume of 1 ml ,
using an Anatech robotic system Scanditronix, Uppsala,
.Sweden . After evaporation of the solvent at 1308C, hydro-
 .gen iodide 57%, 0.8 ml was added by the robot and the
w11 x w11 xC CH I was formed. In this way 30 GBq C labelled3
methyliodide with a specific activity of 150 TBq mmoly1
was obtained 11 min after end of bombardment. The
 .radiochemical yield was 70–90% corrected for decay .
w11 xThe C CH I was trapped into a vial containing a solu-3
tion of the desmethyl precursor 4-benzyloxy-3-formamido-
w  .a- N-benzyl -N- p-hydroxy-a-methylphenethyl aminome-
x   .  .thyl -benzyl alcohol 1.0 mg, mixture of R, R and S,S -
.  .isomers Murase et al., 1977, 1978; Trofast et al., 1991
 . and potassium tert-butoxide 0.2 mg in acetonitrile 0.8
. ml which was placed inside a heating block room tem-
. w11 xperature . After the C CH I was trapped, the heating3
 .block was warmed up to 1108C 4 min and the reaction
mixture was allowed to react for 5 min at this temperature.
To cool down, the reaction vial was placed into cold water
 .for 1 min and acetic acid 1 ml was added to destroy the
base. Then the reaction mixture was added to a vessel
containing a suspension of palladium on activated carbon
 .  .PdrC, 30%, 3 mg in ethanol 0.5 ml . Via a needle a
 y1 .flow of hydrogen 40 ml min was flushed through the
suspension for 15 min. To remove the PdrC, the suspen-
 .sion was filtered Millex-HV, 0.45 mm, Millipore and the
 .filter was extracted with ethanol 1 ml . Subsequently the
solvents were removed by rotary evaporation. The residue
was dissolved in high performance chromatography
 .  .HPLC eluent 1 ml and injected onto the HPLC column
m-Bondapak C-18, 5 mm 3.9=300 mm, Waters Milli-
wpore, mobile phase: water with 0.9% sodium chloride
 .NaCl and 2 mmol of sodium dihydrogen phosphate
 . x .monohydrate NaH PO , pHs3 :ethanols85:15 run-2 4
ning at 1.2 ml miny1. The product had a retention time of
12 min. An experimental sample of formoterol fumarate
obtained from Astra Draco confirmed the identity of the
w11 xFig. 1. Reaction scheme of C formoterol.
( )T.J. Visser et al.rEuropean Journal of Pharmacology 361 1998 35–41 37
.labelled product . The labelled product was collected and
 y1diluted with buffer NaCl, 140 mmol l ; sodium phos-
 . y1 y1.phate Na PO , 9.0 mmol l ; NaH PO , 1.3 mmol l ,3 4 2 4
before injection. The radiochemical yield was 5–15% end
.of bombardment and the specific activity ranged from
y1  y1 .5.5–22.2 TBq mmol 150–600 Ci mmol , 60–70 min
 .after end of bombardment Fig. 1 .
2.3. Dynamic PET-study in male Wistar rats
Animal handling was in accordance with the Law on
Animal Experiments of the Netherlands. PET-studies were
carried out with a Siemens ECAT 951r31 positron cam-
era. Data acquisition was performed using a dynamic
protocol. The in-plane spatial resolution amounted to 6
mm full width half-maximum. During the reconstruction a
zoom factor of 1.5 was applied and the matrix size was
128=128. The rats were anaesthetised with pentobarbital
 y1 .60 mg kg body-weight . The rats were positioned in the
PET camera parallel to the transaxial plane of the tomo-
graph, so sagittal sections were obtained. In six control rats
w11 x wa solution of C formoterol 1.85 MBq, specific activity
y1 x5.6–13 TBq mmol was administered by injection into
 .the tail vein. Five other rats were pre-treated with propra-
 y1 .nolol 2.5 mg kg , within 1 min followed by injection of
a solution of the radioligand 1.85 MBq, specific activity
y1 .5.6–13 TBq mmol . The following time frames were
defined: 8 frames of 15 s, followed by 4 frames of 30 s, 4
frames of 1 min, 4 frames of 2 min, 6 frames of 4 min, and
2 frames of 10 min. Data analysis was performed using
 .Siemens ECAT software V6.5D on a Sun workstation.
2.4. Biodistribution studies in male Wistar rats
w11 x C Formoterol 1.85–2.78 MBq, specific activity:
y1 .14.8–29.6 TBq mmol was intravenously injected into
the tail vein of pentobarbital-anaesthetised male Wistar
 .rats 242"26 g, Ns5 . In blocking experiments the rats
 y1were either pre-treated with propranolol 2.5 mg kg ,
.  y1 .Ns5 , ICI 118551 0.15 mg kg , Ns5 , CGP 20712A
 y1 .  y10.15 mg kg , Ns4 or isoprenaline 15 mg kg ,
.Ns4 in saline, 1 min before injection of the radioligand
1.85–2.78 MBq, specific activity: 14.8–29.6 TBq
y1 .mmol . After 10 min the animals were sacrificed by
extirpation of the heart and the following tissues were
removed: cerebellum, cortex, fat, heart, intestine, kidney,
 .liver, lung, muscle skeletal , spleen, and trachea. Plasma
and an erythrocyte pellet were obtained by centrifugation
 y1 .6000 min , 5 min . Next, the radioactivity was deter-
mined with a gamma counter LKB-Wallac Compugamma
.1282 CS, Turku, Finland and the tissue samples were
weighed.
2.5. Clearance from plasma and metabolism
The carotid artery of anaesthetised rats 258"19 g,
. Ns4 was cannulated and arterial blood samples 0.2 to
.0.3 ml were drawn at 10, 20, 30, 40, 50, 60, 90, 120, 300,
600, 1200, and 2400 s after i.v. injection of 1.85 MBq of
 y1 .labelled formoterol specific activity 11.1 TBq mmol .
Plasma and red blood cells were separated by centrifuga-
 y1tion 2 min, 6000 min , Hettich Zentrifugen, Tuttlingen,
.  .Germany . Plasma 100 ml was then counted in a g-coun-
ter. The clearance curve was analysed by means of a
commercial non-linear regression program EnzFitter, El-
.sevier Biosoft, Cambridge, UK .
Plasma samples for metabolite analysis were acquired
 .from male Wistar rats Ns2, 290"21 g as described
above. Samples were drawn at 0.5, 1, 1.5, 2, 3, 5, 0.25
.  .ml and 10 min 0.5 ml post injection of the radioligand
 y1 .5.55 MBq, specific activity 11.1 TBq mmol . Plasma
and red blood cells were separated by centrifugation 2
min, 6000 miny1, Hettich Zentrifugen, Tuttlingen, Ger-
.many . Subsequently, the plasma was deproteinized with
two volumes of acetonitrile, centrifuged and the super-
natant was injected onto an HPLC column C-18 Radial-
w xpak, 5 mm, mobile phase: Na HPO 50 mM :ethanols2 4
y1 . 66:34, pHs3.0; flow rate 1.3 ml min . Fractions 0.65
.ml of the eluate were collected during 15 min and counted
w11 x  .  .Fig. 2. PET images of b -adrenoceptors in the lungs of male Wistar rats acquired with C formoterol without left image and with right image2
propranol blocking.
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Fig. 3. Time activity curves generated from the lungs of rats acquired
w11 xwith C formoterol with or without propranolol pretreatment. Treated
and untreated groups were significantly different Student’s t-test; P -
.0.05 .
in the gamma counter. The recovery from the column
exceeded 90%.
For analysis of metabolites in lungs, heart, and liver,
 . w11 xrats Ns2, 244"1 g were injected with C formoterol
 y1 .7.4 MBq, specific activity: 14.8 TBq mmol via a tail
vein. After 10 min the rats were sacrificed by extirpation
of the heart. Lungs, heart, and liver were quickly removed
 .and homogenised in a mixture of water 1 vol. and
 .acetonitrile 2 vols. , using a Heidolph diax 600 apparatus
 .Hettich, Tuttlingen, Germany . Subsequently the extracts
 y1 .were centrifuged 5 min, 15 000 min and the super-
natant was analysed by HPLC as described above.
3. Results
3.1. Dynamic PET study in male Wistar rats
In the PET study, lungs were visible in the untreated
rats. After pre-treatment of animals with a non-selective
 .beta-blocker propranolol , the lungs were no longer visi-
 .ble Fig. 2 . The time activity curves generated from the
 .lungs control rats showed a relatively rapid decline to a
 .plateau Fig. 3 . After pre-treatment of rats with propra-
nolol, pulmonary uptake was significantly suppressed Stu-
.dent’s t-test, P-0.05 . If tissue uptake of radioactivity
after propranolol pre-treatment is considered to represent
non-specifically bound radioligand only, ratios of
totalrnon-specific binding can be calculated. Totalrnon-
specific binding increased to 1.8 at 55 min post injection
 .Fig. 6 .
3.2. Biodistribution studies
w11 xThe biodistribution of C formoterol in male Wistar
rats, both untreated and pre-treated with saturating doses of
non-selective and subtype selective b-adrenoceptor ago-
nists and antagonists, is shown in Table 1. Tissue uptake
was determined by ex vivo counting, 10 min post injec-
tion, and expressed as a differential absorption ratio which
 . is defined as cpm recoveredrg tissue r cpm injectedrg
. body weight . Tissues rich in b -adrenoceptors lung,2
.spleen, heart showed high accumulation of radioactivity.
Uptake in cortex and cerebellum, was very low 0.03% of
.the injected dose per gram ; here the tracer did not accu-
mulate over plasma levels.
When the rats were pre-treated with propranolol a
.lipophilic, non-selective b-adrenoceptor antagonist , ra-
dioactivity in heart, intestine, lung, skeletal muscle, red
blood cells and spleen was significantly reduced. Isopre-
naline a hydrophilic, non-selective b-adrenoceptor ago-
. nist and ICI 118551 a lipophilic b -adrenoceptor antago-2
.nist gave comparable results as propranolol. In contrast
uptake in heart, lung, muscle, plasma, red blood cells and
spleen was not affected after pre-treatment of the rats with
 .CGP 20712A a hydrophilic b -adrenoceptor antagonist .1
Table 1
w11 x aBiodistribution of C formoterol in rat
Tissue Control Propranolol ICI 118551 CGP 20712A Isoprenaline
 .  .  .  .  .Ns5 Ns5 Ns5 Ns4 Ns4
Cerebellum -0.1 -0.1 -0.1 -0.1 -0.1
Cortex -0.1 -0.1 -0.1 -0.1 -0.1
Fat 0.24"0.13 0.19"0.12 0.17"0.02 0.25"0.07 0.24"0.05
b b bHeart 2.39"0.23 1.82"0.11 1.70"0.28 2.34"0.54 1.77"0.31
Intestine 1.45"0.61 2.43"1.08 1.81"1.89 1.33"0.12 0.93"0.15
bKidney 10.7"3.6 7.4"2.8 5.5"2.2 10.0"1.9 9.4"1.7
Liver 1.19"0.50 0.87"0.24 0.88"0.16 1.30"0.12 1.32"0.23
b b bLung 4.28"0.39 2.07"0.30 1.86"0.30 4.27"0.26 2.21"0.57
b b b bMuscle 0.53"0.09 0.28"0.03 0.30"0.07 0.40"0.05 0.23"0.04
bPlasma 0.45"0.08 0.38"0.03 0.31"0.06 0.40"0.06 0.40"0.07
b b bRed blood cells 0.44"0.07 0.27"0.07 0.28"0.03 0.38"0.07 0.21"0.03
b b bSpleen 3.11"0.88 1.52"0.16 1.58"0.30 2.87"0.14 1.76"0.26
Trachea 0.77"0.18 0.68"0.07 0.83"0.23 0.93"0.13 0.53"0.15
a Tissue uptake is expressed as a differential absorption ratio and presented as a mean"SD of N independent observations. Differences between treated
and untreated groups were tested using Student’s t-test; Psdual-tail probability.
bSignificantly different from control rats, P-0.05.
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w11 xFig. 4. The clearance of C formoterol from rat plasma. The solid line is
a bi-exponential curve fit.
3.3. Clearance from plasma and metabolism
w11 xThe initial clearance of i.v. injected C formoterol
 .from plasma was very rapid Fig. 4 . The clearance showed
a biphasic pattern with an initial rapid distribution phase
 .half-life: 0.43 min , representing 85% of the injected
 .dose, and a slow elimination phase half-life: 29 min . The
time course of metabolism of the radioligand was also
w11 xanalysed. C Formoterol was substantially metabolised
and radioactive metabolites appeared rapidly in plasma.
The fraction of total plasma radioactivity representing
unmodified radioligand decreased from more than 99.8%
 .at 0 min to less than 15% at 10 min post injection Fig. 5 .
HPLC analyses of tissue extracts acquired 10 min post
injection, indicated that respectively )96%, )94% and
-8% of radioactivity in lungs, heart, and liver represented
the parent compound. The parent compound eluted with a
retention time of 9 min; one hydrophilic radioactive
w11 xFig. 5. Time-course of unchanged C formoterol in plasma. The fraction
of total plasma radioactivity representing unmodified radioligand is plot-
ted. The solid line is a bi-exponential curve fit.
metabolite was observed with a retention time of 3 min. To
determine whether this metabolite is a glucuronide, two
plasma samples were obtained 10 min post-injection. One
was used as a control while the other was incubated with
100 ml of b-glucuronidase solution in 50% glycerol,
pHs6.0, from Escherichia coli, Boehringer Mannheim,
.Germany for 60 min at 228C. HPLC analysis showed that
the untreated control sample contained less than 10% of
the parent compound while in the incubated sample this
was more than 55%.
4. Discussion
w11 xFormoterol was labelled with C in the methoxy
w11 xgroup by reaction of a desmethyl precursor with C CH I.3
Because of the presence of a secondary amine and a
phenolic hydroxyl group which are also able to react with
w11 x  .C CH I, the benzyl-protected precursor 2 Fig. 1 was3
 .  .synthesised as a mixture of R, R and S,S -isomers,
according to a procedure as described by Murase et al.
 .1977, 1978 . After labelling, compound 3 was deprotected
 . w11 xwith PdrC 30% and H to afford C formoterol 1. It2
may still be possible to further optimise the labellingrde-
protection reaction conditions to obtain higher yields. For
instance other protecting groups, which can be removed
more rapidly, may be used.
The biodistribution data clearly demonstrate that the
 .tissues rich in b -adrenoceptors lung, spleen, heart show2
w11 x  .high accumulation of C formoterol Table 1 . But proba-
bly due to its low lipophilicity, uptake of formoterol
 .log Ps0.4, Jeppsson et al., 1989 in cerebral cortex and
cerebellum, tissues with a high proportion of b-adrenocep-
 .tors Minneman et al., 1979; Booze et al., 1989 , was very
 .low 0.03% of the injected dose per gram .
Propranolol pre-treatment resulted in a significant re-
w11 xduction of the uptake of C formoterol in lungs, heart,
and spleen, suggesting that the accumulation in these
 .organs is at least partially receptor-mediated Table 1 . ICI
118551 is lipophilic and shows a 100–300 times higher
affinity for the b than for the b -subtype Bilski et al.,2 1
.1983; Lemoine et al., 1985 . After administration of this
ligand the uptake in tissues containing b -adrenoceptors2
was significantly reduced. CGP 20712A is a hydrophilic
b-adrenoceptor ligand which shows a high selectivity for
 .  .the b subtype 1000–10 000 fold Dooley et al., 1986 .1
Pre-treatment of the rats with CGP 20712A did not signifi-
cantly reduce uptake in the target organs with respect to
the control values. Administration of the hydrophilic, non-
selective b-adrenoceptor agonist, isoprenaline, before in-
jection of the radioligand gave the same results in lungs,
heart, and spleen as propranolol pre-treatment. Thus, the
results of the blocking experiments indicate that formoterol
uptake represents binding of the radioligand to b -adrenoc-2
eptors.
( )T.J. Visser et al.rEuropean Journal of Pharmacology 361 1998 35–4140
 .Metabolism of formoterol is fast. Sasaki et al. 1982
reported a somewhat slower metabolism after intravenous
w3 x  y1 .administration of H formoterol fumarate 50 mg kg to
rats 41, 28, and 24% of radioactivity was unchanged
.parent compound at 5, 30, and 60 min . We found less
than 15% unmetabolised ligand in rat plasma at 5 min post
injection of the radioligand. The difference between
Sasaki’s and our results may be due to the fact that Sasaki
et al. administered a more than 100 times higher dose in
their experiments. Only one metabolite, the 2-O-
glucuronide conjugate of formoterol was detected in urine
 .and bile Sasaki et al., 1982 . We also found that glu-
curonidation is a major metabolic pathway. Since radioac-
 .tivity in the target organs consists mainly )94% of
parent compound, the radioactive metabolites of for-
moterol seem to have negligible affinity to b-adrenocep-
tors and they do not accumulate in the lungs. Of course
glucuronidation can be expected to reduce receptor affinity
substantially and it results in rapid elimination of the
ligand via the kidneys.
w11 xThe ratios of totalrnon-specific binding of C for-
moterol in rat lung are much lower than those of the
 . established b-adrenoceptor antagonist S -4- 3-t-buty-
. w11 xlamino-2-hydroxypropoxy -2 H-benzimidazol-2- C one
 . w11 x .S - C CGP 12177 during the time-course of a PET
w11 xscan. Whereas these ratios for C CGP 12177 rapidly
 .increased to about 7 Van Waarde et al., 1998 , for
w11 x  .C formoterol they rose to approximately 1.8 Fig. 6 .
 .  . w11 xBut a mixture of the R, R and S,S isomers of C for-
moterol was used in these experiments. From the four
 .possible diastereoisomers of formoterol, the R, R -isomer
 .is the most potent Trofast et al., 1991 . Therefore, in
future studies we intend to use enantiomerically pure
 . w11 xR, R - C formoterol, which may improve the targetr
non-target and tissuerplasma ratios. In experiments with
radiolabelled muscarinic antagonists we noticed a doubling
of the totalrnon-specific binding ratios under such condi-
 .tions Visser et al., 1997 .
With these studies we have shown that it is possible to
w11 xdetect specific binding of the agonist radioligand C for-
w11 xFig. 6. Totalrnonspecific binding ratios of C formoterol determined
from the dynamic PET data in absence and presence of propranolol.
moterol to b-adrenergic receptors in vivo with PET.
w11 xWhether C formoterol selectively binds to the high
affinity state of b -adrenoceptors remains to be elucidated.2
w3 xIn vitro binding studies with H formoterol in human and
guinea pig lung membranes revealed binding of formoterol
 .to only one single class of receptors Mak et al., 1994 .
 .Roux et al. 1996 demonstrated that formoterol displaces
w125 xI iodocyanopindolol from guinea pig bronchial b -2
adrenoceptors and these competition curves were best
characterised by a model for two-site interaction; the ago-
nist binds to receptors that are in high pK s9.62"i,high
.  .0.4 and low pK s7.83"0.06 -affinity states. If thisi,low
model for two-site interaction also holds in vivo then it is
 .likely but difficult to prove that the in vivo obtained PET
images of the lungs of rats also represents binding of
w11 xC formoterol to the high affinity state of b-adrenocep-
tors. Under the conditions of a PET study the low affinity
state will not significantly contribute to total tissue binding
since the binding potential of these receptors, that is the
ratio of B and K , is much less than one Scatchard,max D
.1949 .
Since b -adrenoceptor agonists are potent relaxants of2
the airways, a dysfunction in the adrenergic system, e.g., a
reduction in b-adrenoceptor density, and affinity, or a
defect in the coupling of receptors to distal elements of the
transduction chain, may lead to a less effective relaxation
of the airways and may therefore be an important mecha-
nism underlying asthma. Since antagonists do not induce
high affinity states of receptors, antagonist radioligands
will only provide information about the total number of
receptors. Data on the high affinity state can be acquired
only with agonist ligands. Such data can be of clinical
interest because the fraction of receptors in the high affin-
ity state may be altered by disease or after treatment. The
efficacy of agonist drugs may be affected by alterations of
the fraction of receptors in the high affinity state.
5. Conclusion
This is the first time that specific binding to b -adren-2
oceptors was observed in intact animals with PET, after
i.v. administration of a radiolabelled agonist. With the
introduction of this new radioligand a new research tool
has become available to study pulmonary b -adrenocep-2
tors and to examine the mechanisms underlying long dura-
tion of action in b-adrenergic bronchodilators.
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